Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nicotinamide for Skin Cancer Chemoprevention.

JAMA dermatology·2025
Same author

Identifying Borderline Trachoma Grades Using a Three-Latent Class Model.

The American journal of tropical medicine and hygiene·2025
Same author

Long-term outcomes of pelvic-fascia sparing robotic-assisted radical prostatectomy versus standard technique: Superior urinary function and quality of life without compromising oncologic efficacy in a single-surgeon series.

Urologic oncology·2024
Same author

Prognostic Optical Coherence Tomography Biomarkers in Neovascular Age-Related Macular Degeneration.

Journal of clinical medicine·2023
Same author

Prostate sarcoma.

IJU case reports·2023
Same author

Moving on From Retzius: A Call for Change.

Urology·2022

Related Experiment Video

Updated: Jul 10, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Genetics and Screening in Prostate Cancer.

Joseph G R Partuzo1, Belén Mora-Garijo2, Jonathan Hwang1

  • 1Department of Urology, Georgetown University School of Medicine, Washington, DC, USA.

The Surgical Clinics of North America
|July 8, 2026
PubMed
Summary
This summary is machine-generated.

Prostate cancer risk and outcomes are influenced by genetics, with disparities seen in minority populations. Genetic testing and new tools can improve risk stratification and treatment selection for better patient outcomes.

Keywords:
Germline genetic testingHealth disparitiesPolygenic risk scoresPrecision oncologyProstate cancerSomatic mutations

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Experiment Videos

Last Updated: Jul 10, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Area of Science:

  • Oncology
  • Genetics
  • Cancer Research

Background:

  • Prostate cancer is a common, heritable cancer with significant health disparities.
  • Outcomes worsen considerably with advanced or metastatic disease, necessitating better risk assessment.
  • Germline and somatic genetic alterations play a crucial role in prostate cancer.

Purpose of the Study:

  • To review the impact of genetic alterations on prostate cancer.
  • To discuss current and emerging strategies for genetic testing and risk stratification.
  • To highlight novel tools for prostate cancer management.

Main Methods:

  • Literature review of germline and somatic genetic alterations in prostate cancer.
  • Analysis of current guidelines for genetic testing.
  • Evaluation of emerging technologies for risk stratification and treatment selection.

Main Results:

  • Genetic alterations are key drivers of prostate cancer development and progression.
  • Existing guidelines recommend genetic testing for specific indications.
  • New tools like polygenic risk scores and circulating tumor DNA show promise.

Conclusions:

  • Genetic factors significantly influence prostate cancer.
  • Broader genetic testing strategies and novel tools can enhance risk stratification.
  • Personalized approaches informed by genetic insights are crucial for improving prostate cancer outcomes.